"Protection against influenza and its complications in the context of Covid-19” symposium at Options XI
The Covid-19 pandemic has affected influenza circulation globally, surveillance is important to assess the upcoming season. Influenza is back!
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
Biotherapeutics, such as recombinant proteins and monoclonal antibodies, have become mainstays of modern medicine as shown by their increasing number in the WHO Model List of Essential Medicines.
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains.
Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons
We observed the interference between two prevalent respiratory viruses, respiratory syncytial virus (RSV) and influenza A virus (IAV) (H1N1), and characterized its molecular underpinnings in alveolar epithelial cells (A549).
|
9th Influenza Conference 2023
#ESWI2023: Call for abstracts now open
The deadline for abstract submissions is 14 May 2023 23:59 CET.
H7N9 avian influenza virus infection in men is associated with testosterone depletion
Human infections with H7N9 avian influenza A virus that emerged in East China in 2013 and caused high morbidity rates were more frequently detected in men than in women over the last five epidemic waves.
Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly
Seasonal influenza outbreaks, especially in high-risk groups such as the elderly, represent an important public health problem. Prevailing inadequate efficacy of seasonal vaccines is a crucial bottleneck.
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus antigens could form the basis for a universal influenza virus vaccine that has the potential to elicit long-lasting, broadly cross-reactive immune responses.
|
ESWI Airborne: Meet the Members
How does a virus cause disease after transmission?
In this fascinating episode pathomechanism is explained and we learn how recent research has shown that acute virus infections may cause long-term health impairments. Even mild flu during pregnancy can affect susceptibility to disease in offspring.
FluCov: combining data from around the world to understand the impact of COVID-19 on influenza activity
The FluCov Epi-Bulletin provides an overview of the number of positive cases of influenza and SARS-CoV-2 and the percentage of specimens that tested positive from January 2019 onwards in 22 countries across most regions of the world.